Therapeutic dimensions of ACE inhibitors- A review of literature and clinical trials

Kathmandu University Medical Journal

Volumn 3 no. 3, Issue 11, 2005, Pages 296-304

  Prabhu, M ^a   Palaian, S ^b   Malhotra, A ^b   Ravishankar, P ^b   Bista, D ^b   Almeida, R ^b   Mishra, P ^b  

^a MANIPAL TEACHING HOSPITAL   (Nepal)

^b NONE

Author keywords

ACE inhibitors; Atherosclerosis; Diabetic complications; Hypertension; Myocardial infarction

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HUMAN; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS;

EID: 42649090301     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. th edition. United States of America: McGraw-Hill 2001; 1414-30.
2. Chobian AV, Baikis GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure JAMA; 289 (19): 2560-71.
3. Jackson EK. Renin and angiotensin. In: Hardman JG, Limbird LE 'editors'. Goodman and Oilman's. The pharmacological basis of therapeutics. 10th edition. Newyork: McGraw-Hill2001;809-41.
4. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists N Engl J Med; 344 (25): 1649-54.
5. Sweetman SC. Editor. Martindale The Complete Drug Reference. 33rd edition. London, Pharmaceutical Press; 2002. ISBN 0-85369-499-0
6. McEvoy GK, Miller J, Litvak K et al editors. AHFS Drug Information. United States of America: American Society of Health-System Pharmacists; 2003. ISBN 1-58528-039-9
7. Drug information for the healthcare professional. USP DI, 24th edition, Thomson Micromedex; 2004.
8. British national formulary. 46th edition, British medical association, London; 2003.
9. Pitt B. Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995; 16(Suppl K): 49-54.
10. McMahon S, Sharpe N, Gamble G et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 2000; 36(2): 438-43.
11. Yusuf S, Dagenais G, Pogue J et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 154-60.
12. Yusuf S, Sleight P, Pogue J et al. Effect of an angiotensin-converting- enzyme inhibitor, ramipril on cerebrovascular events in high risk patients:the heart outcomes prevention study investigators. N Engl J Med 2000; 342(3): 145-53
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97.
14. Lacourciere Y, Poirier L, Lefebvre J. A comparative review of the efficacy of antihypertensive agents on 24 h ambulatory blood pressure. Can J Cardiol 2000; 16(9): 1155-66.
15. Aurell M, Jensen G. Treatment of renovascular hypertension. Nephron 1997; 75:373-83.
16. Predel HG, Dusing R, Backer A et al. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril. Am J Cardiol 1987; 59:143D-148D.
17. Anon. Canadian led landmark study demonstrates ACE inhibitor ramipril reduces risk of cardiovascular death and life-threatening events. Can J Cardiol 1999; 15 (9): 1027
18. Packer M , Cohn JN. Consensus recommendations for the management of chronic heart failure - Introduction. Amer J Cardiol 1999; 83 (2A): 1A-38A.
19. Williams JF Jr, Bristow MR, Fowler MB et al. Guidelines for the evaluation and management of heart failure; report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on evaluation and management of heart failure). J Am Coll Cardiol 1995; 26:1376-98.
20. Francis GS. Vasodilators and inotropic agents in the treatment of congestive heart failure. Semin Nephrol 1994; 14: 464-78.
21. Anon. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-46.
22. Crazier I, Ikram H. Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure. Drugs 1992; 43:637-50.
23. Packer M. Treatment of chronic heart failure (letter). Lancet 1992; 340:92-95.
24. Struthers AD. The clinical pharmacology of angiotensin converting emzyme inhibitors in chronic heart failure. Pharmac Ther 1992; 53:187-97.
25. Firth BG. Southwestern Internal Medicine Conference: the multifaceted role of angiotensin converting enzyme inhibitors in congestive heart failure. Am J Med Sci 1988; 296:275-88.
26. Lubsen J, Chadha DR, Yotof YT et al. Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. Am J Cardiol 1996; 77:1191-96.
27. Anon. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998; 97:2202-12
28. Ball SG, Hall AS, Murray GD. Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing. J Amer Coll Cardiol 1995; 25 (Suppl 7): 42S-46S
29. Latini R, Maggioni AP, Flather M et al. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation 1995; 92:3132-7
30. Ball SG, Hall AS. What to expect from ACE inhibitors after myocardial infarction. Br Heart J 1994:72 (suppl): S70-S74
31. Sleight P: Vasodilators after myocardial infarction - ISIS IV. Am J Hypertens 1994; 7:102S-105S.
32. Pfeffer MA, Greaves SC, Arnold MO et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: the healing and early after load reducing therapy trial. Circulation 1997; 95: 2643-51.
33. Opie LH. Personal viewpoint: New developments in the therapy of diabetic hypertensive disease. The ABCD study adds to strong evidence favoring the prime use of ACE inhibitors. Cardiovasc Drugs Ther 1998; 12(3):233-238.
34. GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349:1857-63.
35. SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
36. (Cochrane review) Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. The Cochrane Database of Systematic Reviews 1999, Issue 3. Art. No.: CD002183. DOI: 10.1002/14651858. CD002183
37. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomized trial; the HOPE Investigators. Br Med J 2002; 324:699-702.
38. Midvedt K, Stokke ES, Hartmann A. Successful long-term treatment of post-transplant erythrocytosis with losartan. Nephrol Dial Transplant 1996; 11:2495-7
39. Pisani F, Tisone G, Alciati E et al. Role of ACE inhibitors in the treatment of erythrocytosis in patients with renal allograft. Transplant Proc 1994; 26:2602-3.
40. Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache 1995; 35: 470-1.
41. Janini SDN, Scott DGI, Coppock JS et al. Enalapril in Raynaud's phenomenon. J Clin Pharm Ther 1988 13: 145-50.
42. Dixon JS, Bird HA, Martin MF et al. Biochemical and clinical changes occurring during the treatment of rheumatoid arthritis with novel antirheumatoid drugs. Int J Clin Phar Res 1985; 5: 25-33.
43. Martin MFR, McKenna F, Bird HA et al. Captopril: a new treatment for rheumatoid arthritis? Lancet 1984; 1:1325-8.
44. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure; the Valsartan Heart Failure Trial investigators. N Engl J Med 2001; 1345:1667-75.
45. Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002; 17:597-601.
46. Dmgdex evaluations. Micromedex. Thomson healthcare series. Vol 124 (2005)
47. Bicket DP. Using ACE inhibitors appropriately. American family Physician 2002; 66(3):461-8.
48. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Int Med 1992; 117:234-42.
49. Spiers CJ, Dollery CT, Inman WHW et al. Postmarketing surveillance of enalapril II: Investigation of the potential role of enalapril in deaths with renal failure. Br Med J 1988; 297: 830-32.
50. Kostis JB, Shelton B, Gosselin G et al. Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD). Am Heart J 1996; 131:350-5
51. Lacourciere Y. The incidence of cough; a comparison of lisinopril, placebo and telmisartan , a novel angiotensin receptor antagonist. Int J Clin Prac 1999; 53(2):99-103.
52. Fletcher AE, Palmer AJ, Bulpit CJ. Cough with angiotensin converting enzyme inhibitors: how much of a problem? J Hypertens 1994; 12 (Suppl): S 43-S 47.
53. Ajayi AAL, Adigun AQ. Angioedema and cough in Nigerian patients receiving ACE inhibitor (letter). Br J Clin Pharmacol 2000; 50: 81.
54. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation 6th edition. Lippincot Williams and Wilkins. Philadelphia 2002.
55. Advice for patient. Drug information in lay language. USP DI 18th edition Vol II, United States Pharmacopoeia 1997.